TY  - GEN
AU  - Tang,Monica
AU  - O'Connell,Rachel L
AU  - Amant,Frederic
AU  - Beale,Philip
AU  - McNally,Orla
AU  - Sjoquist,Katrin M
AU  - Grant,Peter
AU  - Davis,Alison
AU  - Sykes,Peter
AU  - Mileshkin,Linda
AU  - Moujaber,Tania
AU  - Kennedy,Catherine J
AU  - deFazio,Anna
AU  - Tan,King
AU  - Antill,Yoland
AU  - Goh,Jeffrey
AU  - Bonaventura,Tony
AU  - Scurry,James
AU  - Friedlander,Michael
TI  - PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors
SN  - 1095-6859
PY  - 2019///1024
KW  - Adult
KW  - Aged
KW  - Anastrozole
KW  - adverse effects
KW  - Antineoplastic Agents, Hormonal
KW  - Carcinoma, Ovarian Epithelial
KW  - drug therapy
KW  - Cystadenocarcinoma, Serous
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Neoplasm Grading
KW  - Neoplasm Recurrence, Local
KW  - Ovarian Neoplasms
KW  - Postmenopause
KW  - Progression-Free Survival
KW  - Prospective Studies
KW  - Quality of Life
KW  - Receptors, Estrogen
KW  - metabolism
KW  - Receptors, Progesterone
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.ygyno.2019.06.011
ER  -